These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 30411632)

  • 1. Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
    Di Nunno V; Gatto L; Fragomeno B; Cubelli M; Nobili E; Romano I; Santoni M; Pisconti S; Montironi R; Massari F
    Future Oncol; 2018 Dec; 14(29):2997-2999. PubMed ID: 30411632
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.
    Ahrens M; Scheich S; Hartmann A; Bergmann L;
    Oncol Res Treat; 2019; 42(3):128-135. PubMed ID: 30799404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What advances have been made in immune-therapy for renal cell carcinoma?
    Verzoni E; Grassi P; Ratta R
    Future Oncol; 2017 Apr; 13(8):665-668. PubMed ID: 28183189
    [No Abstract]   [Full Text] [Related]  

  • 4. Current status and limitations of immunotherapy for breast cancer.
    Tokumaru Y; Joyce D; Takabe K
    Surgery; 2020 Mar; 167(3):628-630. PubMed ID: 31623855
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunotherapy in Gastrointestinal Carcinoma - How to Separate Hope from Hype.
    Moehler M
    Oncol Res Treat; 2018; 41(5):264-265. PubMed ID: 29705785
    [No Abstract]   [Full Text] [Related]  

  • 6. Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
    Gao X; McDermott DF; Michaelson MD
    Oncologist; 2019 Jun; 24(6):725-727. PubMed ID: 31036769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma.
    Chang AJ; Zhao L; Zhu Z; Boulanger K; Xiao H; Wakefield MR; Bai Q; Fang Y
    Anticancer Res; 2019 Jun; 39(6):2683-2687. PubMed ID: 31177102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review on the efficacy and safety of immune checkpoint inhibition in renal cell carcinoma.
    Lyu C; Li W; Liu S; Gao S; Zhang H; Hao L; Yu H; Wei W; Song J; Yang Y; Wang C; Zhang Z; Wang N
    Future Oncol; 2018 Sep; 14(21):2207-2221. PubMed ID: 29726696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for kidney cancer: status quo and the future.
    Bedke J; Stühler V; Stenzl A; Brehmer B
    Curr Opin Urol; 2018 Jan; 28(1):8-14. PubMed ID: 29120911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
    Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends.
    Cheung PF; Lutz M; Siveke JT
    Oncol Res Treat; 2018; 41(5):286-290. PubMed ID: 29705789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma.
    Schmidinger M
    Curr Opin Urol; 2018 Jan; 28(1):29-34. PubMed ID: 29045250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing novel immunocombinations in metastatic renal cell carcinoma.
    Santoni M; Massari F; Aurilio G; Mollica V; Cimadamore A; Lopez-Beltran A; Cheng L; Battelli N; Nolé F; Montironi R
    Immunotherapy; 2020 Dec; 12(17):1257-1268. PubMed ID: 32998603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma.
    Amin A; Hammers H
    Front Immunol; 2018; 9():3120. PubMed ID: 30687324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy and prognostic factors.
    Fumagalli LA; Brivio F
    J Clin Oncol; 2006 Sep; 24(25):4218-9; author reply 4219-20. PubMed ID: 16943541
    [No Abstract]   [Full Text] [Related]  

  • 16. Axitinib-ICIs boost the RCC armamentarium.
    Romero D
    Nat Rev Clin Oncol; 2019 Apr; 16(4):207. PubMed ID: 30833679
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma.
    Siefker-Radtke AO; Apolo AB; Bivalacqua TJ; Spiess PE; Black PC
    J Urol; 2018 May; 199(5):1129-1142. PubMed ID: 29113841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments in the management of bladder cancer: Introduction.
    Smith AB
    Urol Oncol; 2018 Mar; 36(3):95-96. PubMed ID: 29158137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment-Cytokines, Targeted Therapy, and Immunotherapy.
    Dutcher JP; Flippot R; Fallah J; Escudier B
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-18. PubMed ID: 32243201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Women's cancer: Advancing molecular and immunotherapy.
    Dorigo O
    Curr Probl Cancer; 2017; 41(1):7. PubMed ID: 28366203
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.